New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease
NCT ID NCT07152340
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammation, and double vision. The goal is to find a more effective and safer first treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI311 (a lab-made antibody that blocks IGF-1 receptors) and glucocorticoids (methylprednisolone, a steroid hormone)
What this could lead to
If successful, this study could show that IBI311 is a safer or more effective first treatment for thyroid eye disease than standard steroid therapy.
What could go wrong
This is a small, early-phase 4 trial with only 64 participants, so results may not apply to everyone. IBI311 may cause side effects like any antibody drug, and it's not yet proven better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGChanghua, Shanghai Municipality, 200003, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
-
Shanghai Changzheng Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••